3840-76-4

Usage

Uses

Used in Pharmaceutical Development:
1-(4-chlorophenyl)-3-(4-methoxyphenyl)urea is utilized as a potential antineoplastic agent, given its capacity to target and inhibit the enzyme carbonic anhydrase IX, which is overexpressed in various cancer types. This makes it a candidate for cancer treatment, particularly in addressing tumors where this enzyme is a significant factor.
Used in Antimalarial Applications:
In the field of antimalarial drug development, 1-(4-chlorophenyl)-3-(4-methoxyphenyl)urea has demonstrated potential activity against malaria-causing parasites. This suggests its use as a starting point for developing new antimalarial therapeutics.
Used in Antifungal Applications:
1-(4-chlorophenyl)-3-(4-methoxyphenyl)urea has also shown promise in antifungal research, indicating its potential use in treating fungal infections. This makes it a compound of interest for further studies in the field of antifungal drug development.
Used in Research:
In the research industry, 1-(4-chlorophenyl)-3-(4-methoxyphenyl)urea serves as a valuable tool for studying biological processes and mechanisms related to cancer, malaria, and fungal infections. Its diverse biological properties make it a versatile compound for probing and understanding these complex diseases.

Upstream product

• 201230-82-2 carbon monoxide 
• 106-47-8 4-chloro-aniline 
• 104-94-9 4-methoxy-aniline 
• 530-62-1 1,1'-carbonyldiimidazole 
• 74-11-3 para-chlorobenzoic acid 
• 696-62-8 para-iodoanisole 
• 199620-14-9 chromium⁽⁰⁾ hexacarbonyl 
• 1073974-15-8 S-p-nitrophenyl N-p-chlorophenylthiocarbamate 
• 84784-25-8 3-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-nitrosourea 
• 104-12-1 p-chlorphenylisocyanate 
• 21368-28-5 4-chlorobenzoyl azide 

Downstream Products

• 84784-25-8 3-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-nitrosourea 
• 87468-14-2 3-(4-chlorophenyl)-1-(4-methoxyphenyl)-1-nitrosourea 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

Palladium-Catalyzed Synthesis of Symmetrical and Unsymmetrical Ureas Using Chromium Hexacarbonyl as a Convenient and Safe Alternative Carbonyl Source

Pd-catalyzed synthesis of urea derivatives from aryl iodides and different aliphatic and aromatic amines using sodium azide and chromium hexacarbonyl is described. In this process, carbonylation of aryl iodides, Curtius rearrangement of aroyl azides, and nucleophilic addition of amines sequentially occur to afford the products in good to excellent yields. This protocol is operationally simple and displays a broad substrates scope.

Scalable, One-Pot, Microwave-Accelerated Tandem Synthesis of Unsymmetrical Urea Derivatives

We report a facile, microwave-accelerated, one-pot tandem synthesis of unsymmetrical ureas via a Curtius rearrangement. In this method, one-pot microwave irradiation of commercially available (hetero)aromatic acids and amines in the presence of diphenylphosphoryl azide enabled extremely rapid (1-5 min) construction of an array of unsymmetrical ureas in good to excellent yields. We demonstrate the utility of our method in the efficient, gram-scale synthesis of key biologically active compounds targeting the cannabinoid 1 and α7 nicotinic acetylcholine receptors.

Catalytic oxidative carbonylation of arylamines to ureas with W(CO) 6/I2 as catalyst

The oxidative carbonylation of aniline to N,N'-diphenylurea was carried out by using W(CO)6 as the catalyst, I2 as the oxidant, CO as the carbonyl source and 4-(dimethylamino)pyridine (DMAP) as base. The reaction conditions were optimized with respect to different bases, molar ratio of DMAP/iodine, temperature, time, and CO pressure. Various p-substituted arylamines can be converted into the respective symmetrical and unsymmetrical N,N'-disubstituted ureas in moderate to good yields. The reaction demonstrated broad tolerance of functionality.

Kinetics and mechanism of the anilinolysis of S-aryl N-arylthiocarbamates in acetonitrile

The aminolysis reactions of S-aryl N-arylthiocarbamates (YC 6H4NH-C(=O)-SC6H4Z, 1) with anilines in acetonitrile are studied. The reaction rates are more influenced by the nucleophilicity of the nucleophile than the nucleofugality of the leaving group, but the change In the effective charge from reactants to the TS for formation of the tetrahedral intermediate is slightly greater in the leaving group (βz from-0.07 to -0.14) than In the nucleophile (βx = 0.04-0.12). The magnitude of the Broensted coefficients are in the range of values that are consistent for a stepwise mechanism with rate-limiting formation of the zwitterionic tetrahedral intermediate. Signs of cross-interaction constants, ρxy (>0), ρxz (>0) and ρyz (0), are all consistent with a stepwise mechanism. It Is concluded that the change of the amine from benzylamines to anilines causes a shift of the aminolysis mechanism from a concerted to a stepwise process. Copyright

DIARYL UREAS AS CB1 ANTAGONISTS

Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.